Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The report found U.S. cancer patients spent $5.6 billion in out-of-pocket costs for cancer treatment in 2018.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
Advocating for yourself is the best medicine.
A cancer diagnosis often means extreme financial stress—and fights with insurance providers.
A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.
Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.
Oncologist wins Senate backing by a vote of 72 to 18.
“Overall, the candidates seemed well informed around HIV/AIDS issues.”
A look at what the law says about buying prescription drugs from Canada.
Insurance companies can no longer implement harmful co-pay accumulator policies.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
Stop me if you’ve heard this one before.
If the price is lowered with a generic version of PrEP, activists say, “we could end the HIV epidemic without a vaccine.”
A look at the 2019 State of the Union address
Older drugs, many on the market for years, are rising in cost much faster than inflation.
A new study examines the clinical and economic impact of new direct-acting antivirals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.